Sarepta Therapeutics, Inc. (SRPT) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Sarepta Therapeutics’s revenue went from $5M in fiscal 2016 to $2.2B in fiscal 2025, growth of about 94.9% a year.
Net income in fiscal 2025 was -$713M, a net margin of -32.5%; the best year in this period was 2024 with $235M.
Over the twelve months to September 30, 2026, revenue was $2.0B and net income -$115M.
Free cash flow was -$307M in fiscal 2025 and positive in 1 of the 10 years shown.
The diluted share count rose 106% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0B | $2.2B | $1.9B | $1.2B | $933M | $702M | $540M | $381M | $301M | $155M | $5M |
| Gross profit | — | $2.2B | — | — | — | — | — | — | — | — | $5M |
| Operating income | -$49M | -$700M | $218M | -$268M | -$536M | -$460M | -$564M | -$706M | -$344M | -$172M | -$267M |
| Net income | -$115M | -$713M | $235M | -$536M | -$703M | -$419M | -$554M | -$715M | -$362M | -$51M | -$267M |
| EPS (diluted) | $-1.37 | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | $-9.71 | $-5.46 | $-0.86 | $-5.49 |
| R&D | $653M | $1.5B | $805M | $877M | $877M | $771M | $722M | $561M | $402M | $167M | $188M |
| Revenue growth | — | +15.6% | +53.0% | +33.3% | +32.9% | +30.0% | +41.8% | +26.5% | +94.7% | +2751.6% | +332.6% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $186M | -$205M | -$206M | -$501M | -$325M | -$443M | $107M | -$456M | -$389M | -$232M | -$246M |
| Capital spending | -$9M | -$102M | -$137M | -$76M | -$31M | -$38M | -$82M | -$60M | -$61M | -$12M | -$5M |
| Free cash flow | $176M | -$307M | -$343M | -$577M | -$356M | -$482M | $25M | -$516M | -$450M | -$244M | -$251M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | $25M | $0 | $0 | — | — | — | — | — | — | — |
| Stock-based pay | $111M | $123M | $184M | $183M | $233M | $114M | $108M | $79M | $50M | $30M | $30M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $940M | $1.4B | $1.7B | $2.0B | $2.1B | $1.9B | $1.1B | $1.2B | $1.1B | $318M |
| Debt | — | $1.0B | $1.3B | $1.4B | $1.6B | $620M | $101M | $56M | $481M | $431M | $18M |
| Equity | — | $1.1B | $1.5B | $859M | $385M | $928M | $762M | $818M | $1.0B | $789M | $337M |
| Total assets | — | $3.3B | $4.0B | $3.3B | $3.1B | $3.1B | $3.0B | $1.8B | $1.6B | $1.3B | $424M |
| Shares (diluted) | 106M | 100M | 108M | 92M | 88M | 81M | 78M | 74M | 66M | 59M | 49M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 98.8% | — | — | — | — | — | — | — | — | 97.6% |
| Operating margin | -2.5% | -31.8% | 11.5% | -21.5% | -57.5% | -65.5% | -104.5% | -185.3% | -114.1% | -111.0% | -4920.3% |
| Net margin | -5.9% | -32.5% | 12.4% | -43.1% | -75.4% | -59.7% | -102.6% | -187.8% | -120.2% | -32.8% | -4930.2% |
| FCF margin | 9.0% | -14.0% | -18.0% | -46.4% | -38.2% | -68.6% | 4.7% | -135.5% | -149.4% | -157.8% | -4633.1% |
| ROIC | — | -25.4% | 6.9% | -9.4% | -21.2% | -29.7% | -51.6% | -63.8% | -22.7% | -11.1% | -59.5% |
| ROE | — | -62.5% | 15.4% | -62.4% | -182.8% | -45.1% | -72.7% | -87.4% | -35.1% | -6.4% | -79.4% |
Frequently asked questions
What is Sarepta Therapeutics’s annual revenue?
$2.2B in fiscal 2025 and $2.0B over the twelve months to September 30, 2026.
How much profit does Sarepta Therapeutics make?
Net income was -$713M in fiscal 2025 (net margin -32.5%).
Is Sarepta Therapeutics’s revenue growing?
Yes: revenue rose 15.6% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.